---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-349160"
form_type: "8-K"
ticker: "FDMT"
cik: "0001650648"
company_name: "4D Molecular Therapeutics, Inc."
filed_at: "2026-08-13T20:06:44+00:00"
generated_at: "2026-08-13T20:09:29.388849+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# 4DMT Q2 net loss $72.9M; 4D-150 Phase 3 enrollment complete, $200M credit facility

## Summary
- Net loss $72.9M vs $54.7M; R&D expenses $68.3M vs $48.0M; G&A $12.5M vs $11.5M.
- Cash $430.6M at June 30, 2026, down from $514.0M; funds into H2 2028.
- 4D-150 4FRONT-1 topline Q2 2027 (N=523); 4FRONT-2 enrollment complete, topline H2 2027.
- PRISM 2-yr data: 78% treatment burden reduction overall, 87% in recently diagnosed; no new inflammation.
- $200M Hercules credit facility, initial draw $20M; DME Phase 3 to start Q3 2026.

## SEC filing metadata
- accession: 0001193125-26-349160
- form_type: 8-K
- ticker: FDMT
- cik: 0001650648
- company_name: 4D Molecular Therapeutics, Inc.
- filed_at: 2026-08-13T20:06:44+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/0001193125-26-349160-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-349160
- JSON: https://secwatch.observer/filing/0001193125-26-349160.json
- Plain text: https://secwatch.observer/filing/0001193125-26-349160.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.